The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme involving nearly 2,680 adults.

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

Unlike injectable diabetes drugs such as Ozempic and Mounjaro, which help lower blood sugar by mimicking hormones that ...

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults ...

Scanning electron microscopy image of an insulin tree-like aggregate. Credit: Wikimedia Commons. For millions of people ...

March 26 (Reuters) - The U.S. Food and Drug Administration has approved Novo Nordisk's insulin injection, Awiqli, to control ...

The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient routines and preferences for adults living with type 2 diabetes ...

Add Yahoo as a preferred source to see more of our stories on Google. Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical trials ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...

For more than 100 years, scientists have pursued the idea of insulin in pill form, often described as a "dream" treatment for ...

In a breakthrough development, researchers have developed a peptide-based oral insulin delivery system that could help ...